Leukemia Could Have A New Healing Touch From The Y3 Proteins Present In The Mushroom
A new research study has suggested that mushroom protein could play a significant role to kill the leukemia cell. The study unveils a new dimension in treating leukemia.
Coprinus comatus or the "shaggy ink cap" is an edible mushroom generally grown in Europe and North America. This particular mushroom is popular for its important nutritional value. It contains antioxidant and famous for its antimicrobial potential. Researchers at the famous University of Florida in Gainesville have revealed a protein exists in this mushroom to kill a certain type of leukemia cell.
Several studies have already hinted the potentiality of the Coprinus comatus elements to treat many health diseases like ovarian cancer, prostate cancer, and HIV. Assistant professor of the famous University of Florida, Dr. Yousong Ding, and his research team have found very important Y3 protein in this edible mushroom. This Y3 protein binds with a specific sugar molecule, the LDNF glycan, generally exists in parasites. Now, it activates the cell-signaling cascade that programs a particular kind of leukemia T cell to commit suicide.
The findings of the research study related to the mushroom and leukemia are available in the Proceedings of the National Academy of Sciences. The researchers have found that the Y3 protein contains the essential glycan binding properties. The GBPs or the glycan binding proteins help to understand the response of the systems to the pathogens. It ultimately helps to prepare new and significant therapeutic pathways.
The researchers tested the important interaction between the LDNF and the Y3 using the model leukemia cells, according to Medical News Today. They noticed that the interaction triggered enzymes that became the ultimate reason for the death of the ninety percent of said leukemia T cells. Now, the outcome of the study explores efficient implications for the treatment of the T cell acute lymphoblastic leukemia.
This specific blood cancer covers almost twenty-five percent of the acute lymphoblastic leukemias. No doubt, this research study explores one significant way in determining functions of the proteins exist in the Coprinus comatus. It can even help to know the impact of the proteins on the unhealthy cells. Now the scientists can have the opportunity to understand more about the Y3 protein functions while studying the leukemia cells.
This new one and the similar studies must be very helpful to unveil pathways for effective drugs in treating leukemia. According to Dr. Ding, these proteins must be important in preventing diseases and health improvement. Within one year Dr. Ding and his research team may begin testing the important actions of the Y3 proteins on the animal models' diseased cells.